{"algorithm_version": "v0.6.0", "applied_rules": {"base_min_final_score": 68.0, "min_bullish_analyses": 2, "min_confidence": 0.62, "min_final_score": 70.0, "min_liquidity_avg_volume": 750000, "regime": "mixed", "regime_score_delta": 2.0}, "benchmark": "SPY", "catalysts": ["October 29-30, 2026: Gilead reported third-quarter product sales of $8.3 billion, up 13% year over year, and adjusted earnings of $2.55 per share, beating analyst expectations.", "October 29-30, 2026: Gilead raised its 2026 base-business sales outlook to $30.7-$31.0 billion, an increase of $900 million from prior guidance.", "Strong growth in HIV, oncology, and liver-disease drug sales.", "Gilead just beat earnings estimates with $2.55 adjusted EPS and $8.3 billion in quarterly sales, up 13% year over year.", "Management raised its full-year 2026 sales outlook by $900 million, signaling strong confidence in the business."], "company_name": "Gilead Sciences", "conviction": "high", "data_quality": 0.885, "date": "2026-10-30", "favorable_models_count": 3, "final_confidence": 0.7754955803330599, "final_score": 81.76533333333333, "generated_at": "2026-10-30T07:30:00.007022-04:00", "horizon": "intraday", "models_answered": 3, "models_asked": 3, "quantitative_score": 67.33, "reason": null, "regulatory_warning": "This is automated, general-audience analysis published for informational purposes only. It is not a personal recommendation, not a promise of performance, and not an invitation to buy or sell any financial instrument. Every investment can lose value, and past results do not predict future ones.", "risks": ["The shares have already risen about 4.0% in one day and 12.3% over 20 sessions, with RSI near 69, increasing the risk of profit-taking after earnings.", "Reported GAAP earnings declined year over year despite the adjusted earnings beat, which could limit upside for investors focused on headline profit.", "The stock has rallied sharply and RSI is near overbought levels.", "Profit-taking could occur after the recent surge.", "RSI is near 70 and the stock is already up over 12% in the past month, meaning much of the good news may already be priced in."], "shortfalls": [], "status": "signal", "summary": "The strongest next-session catalyst is the fresh earnings beat combined with raised 2026 sales guidance and strong HIV-driven growth. The setup is bullish, although the sharp recent rally and elevated RSI could produce a volatile reaction or profit-taking.", "ticker": "GILD", "timezone": "Europe/Zurich", "watchlist": []}